

On page 110, Table 17 after "YLSPGPVTV", please insert -- (SEQ ID NO:116) --.

On page 110, Table 17 after "YLAPGPVTV", please insert -- (SEQ ID NO:117) --.

On page 110, Table 17 after "YLYPGPVTV", please insert -- (SEQ ID NO:118) --.

On page 110, Table 17 after "YLFPGPVTV", please insert -- (SEQ ID NO:119) --.

On page 110, Table 17 after "YLWPGPVTV", please insert -- (SEQ ID NO:120) --.

Remarks

This preliminary amendment to the specification is being made to comply with 37 C.F.R. §1.821(d) which specifies that reference must be made in the specification to a sequence set forth in a Sequence Listing by use of the assigned identifier. In addition, as originally filed, the application contained Figures 5A and 7A which were described, in their respective Figure Legends, as illustrating gp100 sequences with antigenic epitopes underlined in the sequences (page 7, lines 17-22 and page 7, lines 30-35). The peptides presented on page 45, lines 23-25 and page 47, lines 27-31 (specifically SEQ ID NOS:46-48) of the specification are underlined in Figure 7A, not Figure 5A. Therefore these amendments on pages 45 and 47 are being made to correct an inadvertent reference to the wrong Figure. Page 9, line 32 refers to gp100 sequences, the first full paragraph on page 45, lines 6 refers to peptides derived from a gp100 sequence as does the first full paragraph in page 46, lines 1-3. The amendments at page 9, line 32, page 45, line 6, and page 46, lines 3-4 are made to correct the inadvertent reference to only Figure 5A as illustrating gp100 sequence. Figures 5A and 7A were described in the application as filed as illustrating gp100 sequences, and, hence, no new matter is being added by these amendments.

AUTHORIZATION

The Commissioner is hereby authorized to charge any additional fees which may be required for this Amendment, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2026-4124US1.

No additional fees are believed due.

In the event that an extension of time is required in addition to that requested in the petition for an extension of time, the Commissioner is requested to grant a petition for the extension of time which is required

PATENT

2026-4124US1

to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2026-4024US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.


Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Date: February 22, 1996:

Mailing Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154-0053
(212) 758-4800
(212) 751-6849=TELECOPIER

By: 
Carol M. Gruppi
Registration No. 37,341